

10/773,398  
updated Search  
L/Cox 8/17/05

d his

(FILE 'HOME' ENTERED AT 16:05:21 ON 17 AUG 2005)

FILE 'BIOSIS, CAPLUS, EMBASE, MEDLINE, CANCERLIT, JAPIO' ENTERED AT  
16:05:36 ON 17 AUG 2005

L1 7 S (CB10 PEPTIDE)  
L2 4 DUPLICATE REMOVE L1 (3 DUPLICATES REMOVED)  
L3 686 S CB10?  
L4 47 S L3 AND CII?  
L5 45 S L4 AND ARTHRITIS?  
L6 15 DUPLICATE REMOVE L5 (30 DUPLICATES REMOVED)  
L7 14 S L6 NOT L2

=>

d his

(FILE 'HOME' ENTERED AT 16:05:21 ON 17 AUG 2005)

FILE 'BIOSIS, CAPLUS, EMBASE, MEDLINE, CANCERLIT, JAPIO' ENTERED AT  
16:05:36 ON 17 AUG 2005

L1	7 S (CB10 PEPTIDE)
L2	4 DUPLICATE REMOVE L1 (3 DUPLICATES REMOVED)
L3	686 S CB10?
L4	47 S L3 AND CII?
L5	45 S L4 AND ARTHRITIS?
L6	15 DUPLICATE REMOVE L5 (30 DUPLICATES REMOVED)
L7	14 S L6 NOT L2

=>

ANSWER 14 OF 14 EMBASE COPYRIGHT 2005 ELSEVIER INC. ALL RIGHTS RESERVED.  
on STN

AN 91106346 EMBASE

DN 1991106346

TI The role of collagen conformation in type II anticollagen immunity in  
rheumatoid arthritis.

AU Boissier M.C.; Chiocchia G.; Fournier C.

CS Departement de Rhumatologie, Hopital Avicenne, Bobigny, France

SO Revue du Rhumatisme et des Maladies Osteo-Articulaires, (1991) Vol. 58,  
No. 1, pp. 19-24.

ISSN: 0035-2659 CODEN: RRMOA2

CY France

DT Journal; Article

FS 031 Arthritis and Rheumatism

LA French

SL English; Spanish; German

ED Entered STN: 911216

Last Updated on STN: 911216

AB Type II anticollagen (CII) autoimmunity is a frequently  
reported, but non-specific, phenomenon in rheumatoid arthritis  
(RA). The authors show that in 88 sera samples from patients suffering  
from RA, the incidence of antibodies targeted against endogenous human  
CII was the same as that found for 149 control blood donors (14.8%  
versus 11.4%). However, a significant difference was found for the  
incidence of antibodies targeted against the  $\alpha$ -chains of CII  
(26.1% versus 6.0%,  $p < 0.001$ ). As a result of investigating the  
specificity of the anti-CII antibodies in greater detail by  
means of an immunoprinting of the CII peptide fragments obtained  
after splitting the molecule by cyanogen bromide, the authors have  
demonstrated that the largest CII peptides (CB10 and  
CB11) were better recognized than the smaller peptides (CB8, CB9.7), with  
no significant difference between PR and control plasmas. Using  
competitive methods, evidence was obtained in support of heterogeneous  
recognition by the anti-CII antibodies: some recognize  
conformational determinants only, whereas others are targeted against the  
primary sequences of the  $\alpha$ -1 (II) chain.

CT Medical Descriptors:

\*rheumatoid arthritis: ET, etiology

adult

article

autoimmunity

controlled study

female

human

human tissue

immunoblotting

major clinical study

male

Drug Descriptors:

collagen type 2

\*antibody